Fidel De La Cruz-López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fidel De La Cruz-López has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Linda Garcés-Ramírez
Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Unidad Profesional "Adolfo López Mateos", Av. Wilfrido Massieu s/n, Ciudad de México, 52333, México.
6 shared publications - Luis Oskar Soto Rojas
Universidad Nacional Autónoma de México, Facultad de Estudios Superiores Iztacala
6 shared publications - Gonzalo Flores
Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla 72570, Mexico
4 shared publications - Charles R. Harrington
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
3 shared publications Gonzalo Flores
Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla (BUAP), Prol. de la 14 Sur 6301, Ciudad Universitaria, 72592, Heroica Puebla de Zaragoza, México
3 shared publications- José Luna-Muñoz
BioBanco Nacional de Demencias, Universidad Politécnica de Pachuca, Zempoala, México
3 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Elsevier in SSRN Electronic Journal
Enhanced recognition memory, spatial learning and operant conditioning by chronic administration of 1,3-di-o-tolylguanidine in Wistar rat
Sigma chaperone proteins, including sigma-1 (σ-1R) and sigma-2 (σ-2R) receptors, are key regulators of cellular homeostasis and neurotransmission. These proteins are primarily localized in the endoplasmic reticulum and mitochondria-associated membranes, where they regulate calcium signaling, energy metabolism, and synaptic plasticity. Through modulation of voltage- and ligand-gated ion channels, including calcium channels and NMDA receptors, sigma proteins have emerged as promising therapeutic targets in neurodegenerative and cognitive impairment models. However, their role under physiological conditions in healthy subjects remains poorly understood. Therefore, this study evaluated the effects of chronic administration of the non-selective sigma receptor agonist 1,3-di-o-tolylguanidine (DTG) on different forms of learning in experimentally naive, cognitively intact rats. Male Wistar rats received DTG (10 mg/kg) or vehicle for 21 days and were evaluated using the novel object recognition test, operant conditioning in the Skinner box, and the Barnes maze. DTG treatment did not alter locomotor activity. In the novel object recognition task, DTG-treated rats showed increased discrimination index and exploration time during acquisition and memory phases. In operant conditioning, DTG significantly increased lever pressing during acquisition, indicating facilitation of reinforcement learning. In the Barnes maze, both groups exhibited similar spatial learning; however, DTG-treated rats employed more efficient search strategies. Overall, chronic DTG administration induced subtle but consistent cognitive enhancement without affecting motor performance, suggesting a positive modulatory role of sigma chaperone proteins on learning and memory under physiological conditions.
- 8 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEnhanced recognition memory, spatial learning and operant conditioning by chronic administration of 1,3-di-o-tolylguanidine in Wistar rat
Sigma chaperone proteins, including sigma-1 (σ-1R) and sigma-2 (σ-2R) receptors, are key regulators of cellular homeostasis and neurotransmission. These proteins are primarily localized in the endoplasmic reticulum and mitochondria-associated membranes, where they regulate calcium signaling, energy metabolism, and synaptic plasticity. Through modulation of voltage- and ligand-gated ion channels, including calcium channels and NMDA receptors, sigma proteins have emerged as promising therapeutic targets in neurodegenerative and cognitive impairment models. However, their role under physiological conditions in healthy subjects remains poorly understood. Therefore, this study evaluated the effects of chronic administration of the non-selective sigma receptor agonist 1,3-di-o-tolylguanidine (DTG) on different forms of learning in experimentally naive, cognitively intact rats. Male Wistar rats received DTG (10 mg/kg) or vehicle for 21 days and were evaluated using the novel object recognition test, operant conditioning in the Skinner box, and the Barnes maze. DTG treatment did not alter locomotor activity. In the novel object recognition task, DTG-treated rats showed increased discrimination index and exploration time during acquisition and memory phases. In operant conditioning, DTG significantly increased lever pressing during acquisition, indicating facilitation of reinforcement learning. In the Barnes maze, both groups exhibited similar spatial learning; however, DTG-treated rats employed more efficient search strategies. Overall, chronic DTG administration induced subtle but consistent cognitive enhancement without affecting motor performance, suggesting a positive modulatory role of sigma chaperone proteins on learning and memory under physiological conditions.
- Open Access
- 22 June 2026
- Published by Springer Nature in Brain Structure and Function
- Vol. 231 (6) , 90
Auditory conditioned fear elicits anxiety-like behavior and differential neuronal remodeling in the prelimbic and infralimbic cortex of rats
Fear and anxiety are adaptive responses that promote survival. Defensive immobility, including tonic and dorsal forms, is a multisensory behavior. However, the relationship between learned fear and immobility, as well as underlying cortical adaptations, remains unclear. Here, we induced an auditory conditioned fear in adult rats and assessed its effects on locomotion, light/dark preference, and two immobility paradigms, alongside neuroarchitectural changes in the medial prefrontal cortex including the prelimbic (PrL) and infralimbic (IL) cortices. Conditioned rats spent significantly less time in the light compartment and more time in the dark compartment of the light/dark box. In the open-field test, they exhibited reduced distance traveled and increased freezing behavior. Dorsal immobility duration was elevated in conditioned rats, whereas neck-clamp immobility remained unaffected. Morphological analyses revealed region-specific alterations in prefrontal cortical structure: conditioned rats displayed hypertrophy in the PrL cortex, while the IL cortex showed hypotrophy and reduced spine density. These opposing, region-dependent changes suggest differential cortical adaptations associated with learned fear. Together, these results indicate that conditioned rats display behavioral alterations associated with anxiety-related behavior accompanied by selective neuroarchitectural remodeling within prefrontal circuits implicated in fear regulation. Our findings provide novel insights into the interplay between conditioned fear, defensive immobility, and cortical plasticity, highlighting distinct roles of PrL and IL subregions in modulating adaptive and maladaptive responses to threat.
- 22 June 2026
- Published by Springer Nature in Brain Structure and Function
- Vol. 231 (6) , 90
Open AccessAuditory conditioned fear elicits anxiety-like behavior and differential neuronal remodeling in the prelimbic and infralimbic cortex of rats
Fear and anxiety are adaptive responses that promote survival. Defensive immobility, including tonic and dorsal forms, is a multisensory behavior. However, the relationship between learned fear and immobility, as well as underlying cortical adaptations, remains unclear. Here, we induced an auditory conditioned fear in adult rats and assessed its effects on locomotion, light/dark preference, and two immobility paradigms, alongside neuroarchitectural changes in the medial prefrontal cortex including the prelimbic (PrL) and infralimbic (IL) cortices. Conditioned rats spent significantly less time in the light compartment and more time in the dark compartment of the light/dark box. In the open-field test, they exhibited reduced distance traveled and increased freezing behavior. Dorsal immobility duration was elevated in conditioned rats, whereas neck-clamp immobility remained unaffected. Morphological analyses revealed region-specific alterations in prefrontal cortical structure: conditioned rats displayed hypertrophy in the PrL cortex, while the IL cortex showed hypotrophy and reduced spine density. These opposing, region-dependent changes suggest differential cortical adaptations associated with learned fear. Together, these results indicate that conditioned rats display behavioral alterations associated with anxiety-related behavior accompanied by selective neuroarchitectural remodeling within prefrontal circuits implicated in fear regulation. Our findings provide novel insights into the interplay between conditioned fear, defensive immobility, and cortical plasticity, highlighting distinct roles of PrL and IL subregions in modulating adaptive and maladaptive responses to threat.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
The AβpE 3‐42 peptide is associated with a higher degree of inflammation than Aβ1‐40 in brains with Alzheimer’s disease.
Background: Alzheimer’s Disease (AD) is the most common neurodegenerative disease histopathologically characterized by the presence of neuritic plaques (NPs), extracellular deposits composed of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFTs) composed of tau protein. It has been hypothesized that Aβ promotes synthesis and secretes proinflammatory proteins causing neuronal and endothelial damage in the AD brain. In this context, it is not clear if the truncated Aβ species can be more toxic than the full‐length ones. Therefore, this work aimed to explore the association of the Aβ1‐40 peptide (full length) and AβpE3‐42 (truncated species) with inflammation in the brains of AD patients.Method: We used postmortem tissue from the temporal cortex of patients with AD and it was analyzed by confocal microscopy using antibodies against the peptide Aβ 1‐40 and AβpE 3‐42, phospho tau and caspase‐5 (inflammatory type caspase). The amyloidogenic plaques AB1‐40 and AβpE3‐42 and their association with the inflammation marker caspase 5 were quantified. In addition, caspase 5 was quantified by western blot (WB) in control brains and those with AD.Result: We found high caspase‐5 immunoreactivity specifically associated with extracellular Aβ peptide deposits. Interestingly, this caspase 5 is associated preferentially with the truncated Aβ pE 3‐42 peptide. Likewise, caspase‐5 was expressed mainly in brain blood vessels which had Aβ peptide deposits. We did not detect the colocalization of this enzyme with the tau protein. WB assays show increased caspase 5 in AD brains compared to controls.Conclusion: In conclusion, our findings show that the truncated AβpE3‐42 peptide is closely associated with caspase 5, a key enzyme in the inflammation process. This latter may be a specific biomarker of inflammation in AD brains.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessThe AβpE 3‐42 peptide is associated with a higher degree of inflammation than Aβ1‐40 in brains with Alzheimer’s disease.
Background: Alzheimer’s Disease (AD) is the most common neurodegenerative disease histopathologically characterized by the presence of neuritic plaques (NPs), extracellular deposits composed of amyloid beta peptide (Aβ) and neurofibrillary tangles (NFTs) composed of tau protein. It has been hypothesized that Aβ promotes synthesis and secretes proinflammatory proteins causing neuronal and endothelial damage in the AD brain. In this context, it is not clear if the truncated Aβ species can be more toxic than the full‐length ones. Therefore, this work aimed to explore the association of the Aβ1‐40 peptide (full length) and AβpE3‐42 (truncated species) with inflammation in the brains of AD patients.Method: We used postmortem tissue from the temporal cortex of patients with AD and it was analyzed by confocal microscopy using antibodies against the peptide Aβ 1‐40 and AβpE 3‐42, phospho tau and caspase‐5 (inflammatory type caspase). The amyloidogenic plaques AB1‐40 and AβpE3‐42 and their association with the inflammation marker caspase 5 were quantified. In addition, caspase 5 was quantified by western blot (WB) in control brains and those with AD.Result: We found high caspase‐5 immunoreactivity specifically associated with extracellular Aβ peptide deposits. Interestingly, this caspase 5 is associated preferentially with the truncated Aβ pE 3‐42 peptide. Likewise, caspase‐5 was expressed mainly in brain blood vessels which had Aβ peptide deposits. We did not detect the colocalization of this enzyme with the tau protein. WB assays show increased caspase 5 in AD brains compared to controls.Conclusion: In conclusion, our findings show that the truncated AβpE3‐42 peptide is closely associated with caspase 5, a key enzyme in the inflammation process. This latter may be a specific biomarker of inflammation in AD brains.
- Open Access
- 1 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3654
Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease Brains
Alzheimer’s disease (AD) is a neurodegenerative disease, characterized histopathologically by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study, we analyze different Aβ species and their association with the cells that make up the NVU. We evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed against different species of Aβ and the main elements that constitute the NVU. Our results showed that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides, insoluble aggregates are associated with a decrease in the phenotype of the cellular components that constitute the NVU and with BBB disruption. This approach could help identify new therapeutic targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular fibrillar Aβ in AD.
- 1 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3654
Open AccessInsoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease Brains
Alzheimer’s disease (AD) is a neurodegenerative disease, characterized histopathologically by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study, we analyze different Aβ species and their association with the cells that make up the NVU. We evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed against different species of Aβ and the main elements that constitute the NVU. Our results showed that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides, insoluble aggregates are associated with a decrease in the phenotype of the cellular components that constitute the NVU and with BBB disruption. This approach could help identify new therapeutic targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular fibrillar Aβ in AD.
- Open Access
- 18 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4) , 2022
The Neurovascular Unit Dysfunction in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal Aβ or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD.
- 18 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (4) , 2022
Open AccessThe Neurovascular Unit Dysfunction in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal Aβ or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD.
Phenylbutyrate ameliorates prefrontal cortex, hippocampus, and nucleus accumbens neural atrophy as well as synaptophysin and GFAP stress in aging mice
Recent reports on brain aging suggest that oxidative stress and inflammatory processes contribute to aging. Interestingly, sodium phenylbutyrate (PBA) is an inhibitor of histone deacetylase, which has anti‐inflammatory properties. Several reports have suggested the effect of PBA on learning and memory processes, however there are no studies of the effect of this inhibitor of histone deacetylase on aging. Consequently, in the present study, the effect of PBA was studied in 18‐month‐old mice. The animals were administered PBA for 2 months after locomotor activity treatment and Morris water maze tests were performed. The Golgi‐Cox staining technique and immunohistochemistry for glial fibrillary acidic protein (GFAP) and synaptophysin were performed for the morphological procedures. The administration of PBA improves learning and memory according to the Morris water maze test compared to vehicle‐treated animals, which had unchanged locomotor activity. Using Golgi‐Cox staining, dendritic length and the number of dendritic spines were measured in limbic regions, such as the nucleus accumbens (NAcc), prefrontal cortex (PFC) layer 3, and the CA1 of the dorsal hippocampus. In addition, PBA increased the number of dendritic spines in the PFC, NAcc, and CA1 subregions of the hippocampus with an increase in dendritic length only in the CA1 region. Moreover, PBA reduced the levels of the GFAP and increased the levels of synaptophysin in the studied regions. Thus, PBA can be a useful pharmacological tool to prevent or delay synaptic plasticity damage and cognitive impairment caused by age.
Phenylbutyrate ameliorates prefrontal cortex, hippocampus, and nucleus accumbens neural atrophy as well as synaptophysin and GFAP stress in aging mice
Recent reports on brain aging suggest that oxidative stress and inflammatory processes contribute to aging. Interestingly, sodium phenylbutyrate (PBA) is an inhibitor of histone deacetylase, which has anti‐inflammatory properties. Several reports have suggested the effect of PBA on learning and memory processes, however there are no studies of the effect of this inhibitor of histone deacetylase on aging. Consequently, in the present study, the effect of PBA was studied in 18‐month‐old mice. The animals were administered PBA for 2 months after locomotor activity treatment and Morris water maze tests were performed. The Golgi‐Cox staining technique and immunohistochemistry for glial fibrillary acidic protein (GFAP) and synaptophysin were performed for the morphological procedures. The administration of PBA improves learning and memory according to the Morris water maze test compared to vehicle‐treated animals, which had unchanged locomotor activity. Using Golgi‐Cox staining, dendritic length and the number of dendritic spines were measured in limbic regions, such as the nucleus accumbens (NAcc), prefrontal cortex (PFC) layer 3, and the CA1 of the dorsal hippocampus. In addition, PBA increased the number of dendritic spines in the PFC, NAcc, and CA1 subregions of the hippocampus with an increase in dendritic length only in the CA1 region. Moreover, PBA reduced the levels of the GFAP and increased the levels of synaptophysin in the studied regions. Thus, PBA can be a useful pharmacological tool to prevent or delay synaptic plasticity damage and cognitive impairment caused by age.
- Open Access
- 22 April 2020
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 8 (1) , 1-26
Unilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat
The spreading and accumulation of α-synuclein and dopaminergic neurodegeneration, two hallmarks of Parkinson’s disease (PD), have been faithfully reproduced in rodent brains by chronic, oral administration of β-sitosterol β-D-glucoside (BSSG). We investigated whether a single injection of BSSG (6 μg BSSG/μL DMSO) in the left substantia nigra of Wistar rats causes the same effects. Mock DMSO injections and untreated rats formed control groups. We performed immunostainings against the pathological α-synuclein, the dopaminergic marker tyrosine hydroxylase (TH), the neuroskeleton marker β-III tubulin, the neurotensin receptor type 1 (NTSR1) as non-dopaminergic phenotype marker and Fluro-Jade C (F-J C) label for neurodegeneration. Using β-galactosidase (β-Gal) assay and active caspase-3 immunostaining, we assessed cell death mechanisms. Golgi-Cox staining was used to measure the density and types of dendritic spines of striatal medium spiny neurons. Motor and non-motor alterations were also evaluated. The study period comprised 15 to 120 days after the lesion. In the injured substantia nigra, BSSG caused a progressive α-synuclein aggregation and dopaminergic neurodegeneration caused by senescence and apoptosis. The α-synuclein immunoreactivity was also present within microglia cells. Decreased density of dopaminergic fibers and dendritic spines also occurred in the striatum. Remarkably, all the histopathological changes also appeared on the contralateral nigrostriatal system, and α-synuclein aggregates were present in other brain regions. Motor and non-motor behavioral alterations were progressive. Our data show that the stereotaxic BSSG administration reproduces PD α-synucleinopathy phenotype in the rat. This approach will aid in identifying the spread mechanism of α-synuclein pathology and validate anti-synucleinopathy therapies.
- 22 April 2020
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 8 (1) , 1-26
Open AccessUnilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat
The spreading and accumulation of α-synuclein and dopaminergic neurodegeneration, two hallmarks of Parkinson’s disease (PD), have been faithfully reproduced in rodent brains by chronic, oral administration of β-sitosterol β-D-glucoside (BSSG). We investigated whether a single injection of BSSG (6 μg BSSG/μL DMSO) in the left substantia nigra of Wistar rats causes the same effects. Mock DMSO injections and untreated rats formed control groups. We performed immunostainings against the pathological α-synuclein, the dopaminergic marker tyrosine hydroxylase (TH), the neuroskeleton marker β-III tubulin, the neurotensin receptor type 1 (NTSR1) as non-dopaminergic phenotype marker and Fluro-Jade C (F-J C) label for neurodegeneration. Using β-galactosidase (β-Gal) assay and active caspase-3 immunostaining, we assessed cell death mechanisms. Golgi-Cox staining was used to measure the density and types of dendritic spines of striatal medium spiny neurons. Motor and non-motor alterations were also evaluated. The study period comprised 15 to 120 days after the lesion. In the injured substantia nigra, BSSG caused a progressive α-synuclein aggregation and dopaminergic neurodegeneration caused by senescence and apoptosis. The α-synuclein immunoreactivity was also present within microglia cells. Decreased density of dopaminergic fibers and dendritic spines also occurred in the striatum. Remarkably, all the histopathological changes also appeared on the contralateral nigrostriatal system, and α-synuclein aggregates were present in other brain regions. Motor and non-motor behavioral alterations were progressive. Our data show that the stereotaxic BSSG administration reproduces PD α-synucleinopathy phenotype in the rat. This approach will aid in identifying the spread mechanism of α-synuclein pathology and validate anti-synucleinopathy therapies.